NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

PHASE2CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions
Cutaneous NeurofibromaNeurofibromatosis 1
Interventions
DRUG

NFX-179 gel

NFX-179 topical gel is the active investigational product being studied

DRUG

Vehicle gel

NFX-179 vehicle gel is the placebo comparator for this study

Trial Locations (23)

10075

Sadick Research Group, LLC, New York

14623

Skin Search of Rochester, Inc., Rochester

18249

Derm Dox Center for Dermatology, Sugarloaf

20010

Children's National Hospital, Washington D.C.

21287

The Johns Hopkins School of Medicine, Baltimore

24501

The Education & Research Foundation, Inc., Lynchburg

27157

Wake Forest School of Medicine, Winston-Salem

32610

University of Florida, Gainesville

44124

Apex Clinical Research Center, LLC, Mayfield Heights

46250

Dawes Fretzin Clinical Research Group, Indianapolis

55112

Minnesota Clinical Study Center, New Brighton

60077

Northshore University HealthSystem, Evanston

68144

Skin Specialists, P.C., Omaha

72758

Northwest Arkansas Clinical Trials Center, PLLC, Rogers

75230

Dermatology Treatment and Research Center, Dallas

77030

UTHealth McGovern Medical School, Houston

84108

University of Utah, Salt Lake City

90027

Children's Hospital Los Angeles, Los Angeles

92123

University Clinical Trials, Inc., San Diego

94538

Center for Dermatology Clinical Research, Inc., Fremont

97239

Oregon Health & Science University, Portland

72205-7199

University of Arkansas for Medical Sciences, Little Rock

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

NFlection Therapeutics, Inc.

INDUSTRY

NCT05005845 - NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | Biotech Hunter | Biotech Hunter